LLY vs VMD

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Viemed Healthcare Inc. continues to exhibit strong performance and strategic execution within the high-growth tech-enabled home respiratory and chronic care market. Q1 2026 results show impressive 28% YoY revenue growth and an improved gross margin. The company has no net debt and generates substantial, growing free cash flow ($36.3M TTM), supporting its active share repurchase program. Management...